xPedite: A Study to Expedite DIPG and DMG Research
Recruiting now
Conditions studied: Oncology, DIPG, DMG
In brief
This study will gather data from new and existing patients with patient medical records, and patient/family/caregiver reported information to establish a clear natural history of disease suitable to serve as an external, contemporary or historical control arm for future therapeutic development programs of drugs, devices, or biologic interventions in DMG or DIPG.
Key facts
- Study ID
- NCT06140719
- Run by
- xCures
- People needed
- 400
- Starts
- 2023-11-01
- Expected to finish
- 2027-01-01
- Last updated by the study team
- 2024-04-30
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of diffuse midline glioma according to the WHO 2021 Classification of Tumors of the Central Nervous System diagnostic criteria including diffuse intrinsic pontine glioma (DIPG). In the absence of a pathologically confirmed diagnosis, a grade IV glioma involving the thalamus, hypothalamus, brainstem, cerebellum, midbrain, or spinal cord, or with a pontine epicenter and diffuse involvement of the pons.
- Patients with any performance status, comorbidity or disease severity are eligible
- Patients or their legally-authorized representative must be willing and able to provide electronic, informed consent (and assent, if applicable)
- Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088).
- Patients must be a resident of or receiving care within the United States or US territories.
You may not qualify if…
- Patient or legally-authorized representative is unable to provide informed consent.
- Patient or caregiver is unable to complete the PRO and ClinRO by an electronic platform.
Where it is running
- xCures, Inc. — Los Altos, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.